Home » Newsletters » BioWorld Science

BioWorld Science

March 2, 1998

View Archived Issues

Company Profile: Select Therapeutics

Genelabs Technologies: Q4 and year-end 1997 highlights

Anesta: year-end 1997 highlights

Texas Biotechnology: Q4 1997 highlights

Virus Research Institute: Q4 and FY 1997 highlights

Annual Report 1996/1997: Asta Medica

First approvals for Zadaxin outside Asia

Patent coverage for Metabasis Therapeutics' adenosine kinase inhibitors

Novel antiviral agents from Lilly

Bristol-Myers Squibb developing new paclitaxel derivatives

Corvas prepares new orally active antithrombotic agents

S-8921: specific inhibitor of ileal bile acid transport for hypercholesterolemia

Profile of a motilide: Abbott's ABT-229

Takeda in negotiations with potential marketing partner for pioglitazone

Kirin Brewery will collaborate with Chugai on PB-94 development

Antioxidant and neuroprotective effects of GSNO confirmed

Yamanouchi terminates IFN marketing agreement with Schering-Plough

Nicotine inhaler launched in U.S.

Gene delivery technology offered for licensing

ICAgen issued patents on novel ion channel drug discovery technology

Naked DNA delivery technology offered for licensing

LXR and Copernicus establish cancer gene therapy collaboration

Pharmacodynamics of HMR-3647 against respiratory pathogens, enterococci and B. fragilis

New company created for development of cell therapies

Lilly glycopeptide antibiotic compared to vancomycin and teicoplanin in vitro

New compound for mucositis in development at Alizyme

HBED proposed as alternative to deferoxamine as iron chelator

FDA requests additional information for EchoGen NDA review

NIH offers new technology for licensing

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...